Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
The Lancet. HIV|October 5, 2018
Clinically relevant thresholds for ultrasensitive HIV drug resistance testing: a multi-country nested case-control studySeth C Inzaule, Raph L Hamers, Marc Noguera-Julian, et al.
Open Forum Infectious Diseases|May 2, 2022
Dolutegravir Resistance in Malawi's National HIV Treatment ProgramJoep J van Oosterhout, Chifundo Chipungu, Lyse Nkhoma, et al.
The Journal of Antimicrobial Chemotherapy|April 5, 2023
Resistance is common in paediatric patients failing ART in South AfricaGillian M Hunt, Mukhlid Yousif, Leon Levin, et al.
Diagnostics (Basel, Switzerland)|July 14, 2023
Advancing HIV Drug Resistance Technologies and Strategies: Insights from South Africa's Experience and Future Directions for Resource-Limited SettingsKim Steegen, Gert U van Zyl, Mathilda Claassen, et al.
Journal of the International AIDS Society|June 10, 2020
Drug level testing as a strategy to determine eligibility for drug resistance testing after failure of ART: a retrospective analysis of South African adult patients on second-line ARTLucas E Hermans, Kim Steegen, Rob Ter Heine, et al.
Viruses|January 23, 2024
Virological Findings and Treatment Outcomes of Cases That Developed Dolutegravir Resistance in Malawi's National HIV Treatment ProgramHope Kanise, Joep J van Oosterhout, Pachawo Bisani, et al.
The Journal of Antimicrobial Chemotherapy|June 26, 2016
Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan AfricaT Sonia Boender, Cissy M Kityo, Ragna S Boerma, et al.
AIDS (London, England)|May 24, 2022
Long-term HIV treatment outcomes and associated factors in sub-Saharan Africa: multicountry longitudinal cohort analysisSeth C Inzaule, Stefanie Kroeze, Cissy M Kityo, et al.
Medicine|September 14, 2020
High levels of HIV drug resistance among adults failing second-line antiretroviral therapy in NamibiaMichael R Jordan, Ndapewa Hamunime, Leonard Bikinesi, et al.
Viruses|June 26, 2026
Optimizing HIV-1 Genotypic Resistance Testing for Low- and Middle-Income Countries: High-Impact HIV-1 Mutations Across WHO-Defined ScenariosRobert W Shafer, Kaiming Tao, Tom Loosli, et al.
Pageof 5